Cannabis Health

Medical Cannabis Awareness Week (1-7 November), launched by PLEA in 2020, brings patient advocates to cities across the UK to educate the public on accessing legal cannabis-based medicines. Events in Belfast, Birmingham, Glasgow, Cardiff, and London will share personal stories to deepen understanding of the benefits of medical cannabis for various conditions. Read below for the full story 👇 https://lnkd.in/e3F5gJ3H

International Cannabis Weekly - Issue 372 🗞 🌿 Three out of four U.S. cannabis reform bills expected to pass this November 🇪🇺 European Commission launches investigation into #Italy’s CBD flower ban 💰 Budget amendment could revive #France’s medical cannabis programme This and more in Issue 370 of ICW 👉🏻 https://lnkd.in/ebWa_7XC Mentions: Business of Cannabis, Business of Cannabis | Europe, Cannabis Health, CannaReporter®, MJBiz, Benzinga, Ben Stevens, Flora Growth (FLGC), Hypera Pharma, Elixinol Wellness Limited, European Parliament, EIHA - European Industrial Hemp Association, HempToday®, Glass Pharms, Newsweed, Glass Pharms, Marijuana Moment, The Hill Times, Mugglehead, Cannabiz, NL Times, Cantourage, Avextra, Bedrocan, MyAccess Clinics

Six years after the legalisation of medical cannabis in the UK, private prescriptions have increased significantly, with a 118% rise in unlicensed cannabis-based medicines between 2021 and 2023. Despite 35,000 patients now holding prescriptions, broader awareness among healthcare professionals and the public remains limited. While patient numbers are growing, the sector still faces a major knowledge gap. Read here: https://lnkd.in/eNiQstDN Mentions: Releaf, Drug Science, Liverpool John Moores University, Medico Legal, Helen Beckett Wilson, Dr. Lindsey Metcalf McGrath, Tim Kirby

Prescribing medical cannabis for chronic pain could save the NHS almost £4 billion annually, according to new research. The findings come from an independent economic analysis of medical cannabis for the treatment of chronic pain, undertaken by York Health-Economics Consortium at the University of York. https://lnkd.in/dQd5cZnd

International Cannabis Weekly - Issue 371 🗞 🌿 Kamala Harris pledges to federally legalise adult-use cannabis 🌱 German medical cannabis market tipped to top €1 billion by 2028 🧪 UK launches two clinical trials into cannabis and childhood epilepsy This and more in Issue 371 of ICW 👉🏻 https://lnkd.in/exR-pu8w Mentions: Business of Cannabis, Business of Cannabis | Europe, Cannabis Health, CannaReporter®, MJBiz, Benzinga, Alexander Khourdaji, Lawrence Purkiss, Ben Stevens, Canopy Growth Corporation, European Parliament, EIHA - European Industrial Hemp Association, HempToday®, Glass Pharms, Newsweed, GrowLab Organics, Marijuana Moment, The Hill Times, Bubble Bud Inc., Mugglehead, Cannabiz, NL Times, Cantourage, Avextra, Bedrocan, MyAccess Clinics

In the UK, researchers say they are working to get two long-awaited NHS clinical trials underway to investigate the role of cannabis-based medicines in severe forms of epilepsy. The first significant update on the trials—first promised in 2019 following a government review—comes almost six years on from the legalisation of medical cannabis in the UK. Led by researchers at University College London and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the studies are expected to begin recruiting 500 patients in 2025. Read here 👉 https://lnkd.in/eRUhqVSW Mentions: Great Ormond Street Hospital for Children NHS Foundation Trust, Finbar O'Callaghan, UCL, Hannah Deacon, Michael Barnes, Jazz Pharmaceuticals, Matt Hughes, MedCan Family Foundation

International Cannabis Weekly 🗞️ 👨⚖️ California’s controversial hemp ban faces ‘temporary restraining order’ 📈 Poland nearly doubles medical cannabis import limits for 2024 🌿 German medical cannabis market to top €420m in 2024 This and more in Issue 370 of ICW 👉🏻 https://lnkd.in/eDcMz-22 Mentions: Business of Cannabis, Business of Cannabis | Europe, Cannabis Health, CannaReporter®, MJBiz, Benzinga, Alexander Khourdaji, Lawrence Purkiss, Ben Stevens, Canopy Growth Corporation, European Parliament, Gavin Newsom, EIHA - European Industrial Hemp Association, The James Hutton Institute, Glass Pharms, Newsweed, GrowLab Organics, Marijuana Moment, The Hill Times, Bubble Bud Inc., Mugglehead, Cannabiz, Times of Malta

The THC-based drug #dronabinol has been shown to reduce agitation in Alzheimer’s patients without adverse effects. Researchers have shown that a pill form of the drug dronabinol, an FDA-approved synthetic version of THC, reduces agitation in patients with Alzheimer’s by an average of 30%. The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as #delirium or #seizures. #Alzheimer’s disease is the most common #neurodegenerative disease in the United States, with an estimated 6.7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060. https://lnkd.in/e9cpzhfF

On Monday 30 September, the Ministry of Health published a draft royal decree for public hearing, setting out the proposed regulations for the prescription of cannabis-based medicines. After years of campaigning for access to safe and legal cannabis medicines, patients have been critical of how restrictive the proposed regulations are. “They have made it so restrictive… I think this is a mistake,” Carola Pérez, president of the Spanish Observatory of Medicinal Cannabis [Observatorio Español del Cannabis Medicinal, OECM] which celebrates its 10th anniversary this month, tells Cannabis Health. https://lnkd.in/epk9TKmi

A new paper highlights how current policies, and a lack of training for professionals, are contributing to 'stigmatising attitudes' and 'inequalities' among medical cannabis patients in the UK. https://lnkd.in/ea_zwaNY